Lesfal solution for injections 50 mg/ml. ampoules 5 ml. №5

Description

Lesfal Composition:
active substance: 1 ml of solution contains 50 mg of phosphatidylcholine from soybeans;

excipients: benzyl alcohol, deoxycholic acid, sodium chloride, sodium hydroxide, riboflavin (E 101), water for injection.

Lesfal Dosage form.
Injection.

Basic physical and chemical properties: transparent yellow solution.

Lesfal Pharmacotherapeutic group.
Hepatotropic drugs. ATX code A05B A.

Lesfal Pharmacological properties.
Pharmacodynamics.

In liver diseases, the membranes of hepatocytes and their organelles are always damaged, which can lead to a change in the activity of membrane-bound enzymes and receptor systems, a violation of the metabolic function of the cell and a decrease in the intensity of liver regeneration.

The phospholipids contained in Lesfal are similar in chemical structure to endogenous phospholipids, but far outweigh them due to the high content of polyunsaturated (essential) fatty acids. These high-energy molecules are incorporated predominantly into the structures of cell membranes and facilitate the repair of damaged liver tissue. Since the cis-double bonds of these polyenoic acids prevent the parallel arrangement of the hydrocarbon chains of membrane phospholipids, the density of the arrangement of phospholipid structures decreases, as a result of which the rate of intake and excretion of substances increases. Membrane-bound enzymes form functional units that can enhance their activity and ensure the physiological course of basic metabolic processes. Phospholipids affect the disturbed lipid metabolism by regulating lipoprotein metabolism, as a result of which neutral fats and cholesterol are converted into forms suitable for transport, especially due to an increase in the ability of high density lipoproteins (HDL) to bind cholesterol, and are directed for further oxidation. During the excretion of phospholipids through the biliary tract, the lithogenic index decreases and bile stabilizes.

Pharmacokinetics.

When taken orally, more than 90% of the drug is absorbed in the small intestine. The main amount is cleaved by phospholipase-A to 1-acyl-lyso-phosphatidylcholine, 50% of which is immediately reacetylated into polyunsaturated phosphatidylcholine even during absorption in the small intestine. Polyunsaturated phosphatidylcholine enters the bloodstream with lymph flow and from there, mainly in combination with HDL, is transported to the liver. The maximum content of phosphatidylcholine in the blood 6-24 hours after oral administration is on average 20%.

The half-life of the choline component is 66 hours, for saturated fatty acids – 32 hours.

In the course of kinetic studies in the human body, less than 5% of each of the introduced isotopes 3H and 14C was excreted in the feces.

Clinical characteristics.
Indications.
Non-alcoholic steatohepatitis, alcoholic steatohepatitis, acute and chronic hepatitis of various etiologies, liver cirrhosis, pre- and postoperative treatment for surgical intervention on the liver and biliary tract, toxicosis of pregnant women, psoriasis, radiation syndrome.

Contraindications
Hypersensitivity to any component of the drug.

Lesfal should not be administered to newborns and premature babies, since the drug contains benzyl alcohol.

Interaction with other medicinal products and other types of interactions.
Do not use electrolyte solutions to dilute the drug.

Features of the application.
When diluting Lesfal for the preparation of infusion solutions (if it is impossible to use the patient’s own blood), electrolyte-free solutions should be used, namely: 5% or 10% glucose solution (in a 1: 1 ratio), 5% xylitol solution.

Use only clear solution.